A Phase II, Multi-Center Open-Label, Repeat-Dose of Forodesine Hydrochloride (BCX-1777) Infusion in Patients With Advanced T-Cell Leukemia With an Option of Long-Term Forodesine Hydrochloride (BCX-1777) Use.

Trial Profile

A Phase II, Multi-Center Open-Label, Repeat-Dose of Forodesine Hydrochloride (BCX-1777) Infusion in Patients With Advanced T-Cell Leukemia With an Option of Long-Term Forodesine Hydrochloride (BCX-1777) Use.

Completed
Phase of Trial: Phase II

Latest Information Update: 18 Jan 2012

At a glance

  • Drugs Forodesine (Primary)
  • Indications Acute lymphoblastic leukaemia; T cell prolymphocytic leukaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 18 Jan 2012 Actual end date (Dec 2007) added as reported by ClinicalTrials.gov.
    • 17 Jan 2008 Status change from suspended to completed.
    • 04 Apr 2007 Status changed from recruiting to suspended.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top